Insulet Corporation makes, sells, and develops its proprietary Omnipod System, an automated insulin pump for insulin-dependent diabetics in the U.S. and Internationally. Their business operates on a razor-and-blade model centered on its Omnipod system, pairing its low-cost controller (the razor hardware) with its disposable (replaced every 3 days) insulin pods (the consumable blades) that generate recurring, high-margin revenue and strong cash flow visibility. Financially, the company has delivered a decade of consistent high growth, with revenue expanding from under $1B in 2020 to ~$2.7B in 2025 (roughly a 25–30% annual growth rate in recent years), including its 10th consecutive year of 20%+ growth and accelerating ~30% growth in 2025. Profitability has scaled alongside revenue, with gross margins around ~70%+ and operating leverage improving as volumes increase, though near-term earnings can fluctuate due to reinvestment in sales and R&D. Looking forward, management continues to guide to ~20%+ revenue growth with even faster EPS expansion, driven by international expansion, penetration of the large Type 2 diabetes market, and deeper integration with leading automated insulin delivery ecosystems such as Dexcom's G7 and Abbott's FreeStyle Libre. Overall, Insulet offers investors a rare combination of durable recurring revenue, strong historical execution, and a long runway for growth in an underpenetrated global market.
Insulet is highly rated by analysts. The average target price of the 25 analysts currently covering the company is +81.0% above today's stock purchase price. In addtion, Morningstar has a 5-star strong buy rating and CFRA a 4-star buy rating.
As detailed below, a potential return-on-investment result is +3.0%
absolute return-on-investment (equivalent to +49.0% annualized return-on-investment over the next 22 days) if the stock is assigned on the June 18th, 2026 options expiration date.
Insulet Corporation (PODD) -- New Covered Call Position
The simultaneous buy/write transaction today was as follows:
5/27/2026 Bought 100 Insulet Corp. shares @ $144.07
5/27/2026 Sold 1 PODD 6/18/2026 $135.00 Call option @ $12.95 per share
Note: the Implied Volatility of the Call was 54.2 when this transaction was executed. As I prefer, this value greatly exceeds that of the S&P 500 Volatility Index (VIX) which is currently at 16.5.
A possible overall performance result (including commission) for this Insulet Covered Call position if assigned on the options expiration date is as follows:
Covered Call Cost Basis: $13,112.67
= ($144.07 - $12.95) * 100 shares + $.67 commission
Net Profit Components:
(a) Option Income: +$1,294.33
= ($12.95 * 100 shares) - $.67 commission
(b) Dividend Income $0.00
(c) Capital Appreciation (If Insulet shares assigned at the $135.00 strike price on the options expiration date): -$907.00
+($135.00 strike price - $144.07 stock purchase price) * 100 shares
